SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-578637
Filing Date
2016-05-05
Accepted
2016-05-05 07:02:10
Documents
71
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d165905d10q.htm 10-Q 438877
2 EX-31.1 d165905dex311.htm EX-31.1 9081
3 EX-31.2 d165905dex312.htm EX-31.2 9501
4 EX-32.1 d165905dex321.htm EX-32.1 6318
  Complete submission text file 0001193125-16-578637.txt   3712354

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20160331.xml EX-101.INS 595695
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20160331.xsd EX-101.SCH 54900
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20160331_cal.xml EX-101.CAL 64705
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20160331_def.xml EX-101.DEF 303099
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20160331_lab.xml EX-101.LAB 400848
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20160331_pre.xml EX-101.PRE 360637
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 161621510
SIC: 2834 Pharmaceutical Preparations